AP-111: FpFpF: 2’-deoxy-2’,2’-difluorocytidinyl 3’-5’phosphate 2’-deoxy-2’,2’-difluorocytidinyl 3’-5’ phosphate-2’-deoxy-2’,2’-difluorocytidine.
AP-112: 5’-FpFpF-3’-palmitoyl: 2’-deoxy-2’,2’-difluorocytidinyl 3’-5’ phosphate 2’-deoxy-2’,2’-difluorocytidinyl 3’-5’ phosphate-2’-deoxy-2’,2’-difluorocytidinyl 3’-5’ phosphate-1-α(6-(palmitoylamino)hexyl)-2-deoxy-D-ribose

Gemcitabine is a cytidine antimetabolite considered as a highly interesting anticancer drug because of its lower toxicity as compared to other chemotherapeutic agents. However, although gemcitabine has a strong cytotoxic activity in vitro, it has to be given to cancer patients at high doses (above 1000 mg/m2 per dose). This is likely due to degradation of gemcitabine in serum and liver and the development of resistance to the drug by a subset of tumor cells in the treated patients

AP-111 and AP-112 solve the problem of low efficacy of and resistance to gemcitabine therapy for the treatment of patients in need thereof

by providing higher antitumor activity by facilitating the uptake by the cells and the targeting of the drug to tumor cells

and by increasing the stability of dFdC in serum

 

SARS-Cov2

We have initiated two SARS-CoV-2 research projects

• AP-SARS-Cov2-P01-20:aimed at identifying epitopes targeted by cytotoxic T cells to develop a therapy
• AP-SARS-Cov2-P02-20: intended to neutralize and induce immune responses to the virus